Skip the chemo: Millions of breast cancer patients could be spared chemotherapy with groundbreaking genomic test
A groundbreaking international trial, Optima, reveals a genomic test, Prosigna, can identify breast cancer patients unlikely to benefit from chemotherapy.
This precision oncology approach analyzes tumor genes, potentially sparing thousands of women the harsh side effects of chemo while maintaining similar survival rates.
The findings promise a more personalized and less burdensome cancer treatment future.
Breast Cancer Test Breakthrough
- Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy The Guardian —
- Breast cancer patient spared chemotherapy through groundbreaking trial says it felt ‘like Christmas’ ITV —
- Doctors hail cancer injection that can destroy entire tumors The Independent —
- ‘ADC therapy effective in cancer treatment’ Times Of India —
- Cancer jab can eradicate entire tumours in patients, trial shows Irish Times —